Trifluoroescaline
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Trifluoroescaline (TFE), also known as 4-(2,2,2-trifluoroethoxy)-3,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline.[1][2][3] It is a trifluorinated derivative of escaline.[1][2][3]
- None
| |
| Clinical data | |
|---|---|
| Other names | TFE; 3,3,3-Trifluoroescaline; 3,3,3-TFE; F3EM; 4-(2,2,2-Trifluoroethoxy)-3,5-dimethoxyphenethylamine; 3,5-Dimethoxy-4-(2,2,2-trifluoroethoxy)phenethylamine |
| Routes of administration | Oral[1][2][3] |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | 12–18 hours[1][2][3] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C12H16F3NO3 |
| Molar mass | 279.259 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The drug has a dose range of 35 to 65 mg orally and a duration of 12 to 18 hours.[1][2][3] It has similar potency to escaline, greatly increased potency relative to mescaline, and a prolonged duration compared to both mescaline and escaline.[1][2][3] The effects of trifluoroescaline have been reported to include enhanced fantasy, strong closed-eye visuals, significant open-eye visuals, and low body load.[1]
The drug is a low-potency partial agonist of the serotonin 5-HT2A receptor and also interacts with other serotonin receptors and targets.[3]
The chemical synthesis of trifluoroescaline has been described.[4]
Trifluoroescaline was first described in the scientific literature by Daniel Trachsel in 2002.[1][2][3][4] Its pharmacology was studied in more detail in 2021.[3] It is not a controlled substance in Canada as of 2025.[5]